Theriva Biologics Inc (TOVX)

[Ann1]

From the conference call:

"I would like to let everyone know that we were pleased to announce today that SYN-004, our candidate for the prevention of C. difficile infections, was selected as a 2013 Top Project to Watch in infectious disease area by Elsevier Business Intelligence. And related to this, we will be presenting at the 2013 Therapeutic Area Partnerships Conference next Tuesday, November 19, in Boston. As we look forward, we will also be presenting at the LD Micro Conference in early December out in LA." - Kris Maly (Communications)


This is excellent news!

Also, Riley spoke of Trimesta as being the most current impending value driver. The study officially ends in December with results due out 1H 2014. Only so much time to get in at these levels, IMO. The slight whiff of good news, combined with the low float, sends SYN to the moon. IMO